Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
It remains in clinical trials globally, with Phase 3 studies ongoing
The ability of GLP-1 medications to address both blood sugar control and weight management makes them a valuable asset for people seeking to improve their metabolic health
While gastroparesis is not a commonly reported side effect of Ozempic, it is important to understand how GLP-1 RAs like Ozempic might influence gastrointestinal motility and potentially contribute to gastroparesis in some individuals
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
